Cargando…
Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers
Numerous immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), have been approved for the treatment of genitourinary (GU) malignancies. While ICIs have improved treatment outcomes and expanded treatment options, they can cause immune-related adverse events (irAEs). The scope of irAE...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949122/ https://www.ncbi.nlm.nih.gov/pubmed/35330111 http://dx.doi.org/10.3390/life12030360 |